"The U.S. Food and Drug Administration today approved Viberzi (eluxadoline) and Xifaxan (rifaximin), two new treatments, manufactured by two different companies, for irritable bowel syndrome with diarrhea (IBS-D) in adult men and women.
(Generic versions may still be available.)
IBS with Constipation
In Phase 3 clinical trials 2,632 female and male patients received Zelnorm® (tegaserod maleate) 6 mg b.i.d. or placebo. The frequency and type of adverse events for females and males were similar. The following adverse experiences were reported in 1% or more of patients who received Zelnorm (tegaserod maleate) and occurred more frequently on Zelnorm (tegaserod maleate) than placebo:
|Adverse Events Occurring in 1% of IBS Patients and More Frequently on Zelnorm® (tegaserod maleate) than Placebo|
|System/ Adverse Experience||Zelnorm® 6 mg b.i.d. (n=1,327)||Placebo (n=1,305)|
|Gastrointestinal System Disorders|
|Central and Peripheral Nervous System|
|Body as a Whole - General Disorders|
|Leg Pain||1%||< 1%|
Musculoskeletal System Disorders
Chronic Idiopathic Constipation
In phase 3 clinical trials 2,603 male and female patients received Zelnorm (tegaserod maleate) 6 mg b.i.d., 2 mg b.i.d. or placebo. The following adverse experiences were reported in 1% or more of patients who received Zelnorm (tegaserod maleate) and occurred more frequently than in patients who received placebo.
|Adverse Events Occurring in 1% of Chronic Idiopathic Constipation Patients And More Frequently On Either Dose of Zelnorm® Than Placebo|
|System/ Adverse Experience||Zelnorm® 6 mg b.i.d. (n=881)||Zelnorm® 2 mg b.i.d. (n=861)||Placebo (n=861)|
Gastrointestinal System Disorders
|Abdominal pain upper||2%||2%||2%|
|Central and Peripheral Nervous System|
|General disorders and administration site conditions|
|Infections and infestations|
|Upper respiratory tract infection||4%||3%||2%|
|Musculoskeletal and connective tissue disorders|
|Reproductive system and breast disorders|
Respiratory, thoracic and mediastinal disorders
Zelnorm (tegaserod maleate) was not associated with changes in ECG intervals.
Zelnorm (tegaserod maleate) -Induced Diarrhea
IBS with Constipation
In the Phase 3 clinical studies, 8.8% of patients receiving Zelnorm (tegaserod maleate) reported diarrhea as an adverse experience compared to 3.8% of patients receiving placebo. The majority of the Zelnorm (tegaserod maleate) patients reporting diarrhea had a single episode. In most cases, diarrhea occurred within the first week of treatment. Typically, diarrhea resolved with continued therapy. Overall, the discontinuation rate from the studies due to diarrhea was 1.6% among the Zelnorm (tegaserod maleate) -treated patients. In clinical studies, a small number of patients (0.04%) experienced clinically significant diarrhea including hospitalization, hypovolemia, hypotension and need for intravenous fluids. Diarrhea can be the pharmacologic response to Zelnorm (tegaserod maleate) .
Chronic Idiopathic Constipation
In the two Phase 3 studies, 6.6% of patients treated with Zelnorm (tegaserod maleate) 6 mg b.i.d. and 4.2% of patients treated with Zelnorm (tegaserod maleate) 2 mg b.i.d. reported diarrhea as an adverse event, versus 3.0% of patients receiving placebo.
The diarrhea episodes experienced by patients treated with tegaserod occurred early after initiation of treatment (median of 5.5 days), were of short duration (median of 2.5 days), and occurred only once in the majority of patients.
Typically, diarrhea resolved with continued therapy; only 0.9% of patients treated with Zelnorm (tegaserod maleate) 6 mg b.i.d. discontinued the study due to diarrhea (compared to 0.3% in the Zelnorm (tegaserod maleate) 2 mg b.i.d. group and 0.2% in the placebo group).
Abdominal Surgeries, Including Cholecystectomy
An increase in abdominal surgeries was observed on Zelnorm (tegaserod maleate) (9/2,965; 0.3%) vs. placebo (3/1,740; 0.2%) in the Phase 3 IBS clinical studies. The increase was primarily due to a numerical imbalance in cholecystectomies reported in patients treated with Zelnorm (tegaserod maleate) (5/2,965; 0.17%) vs. placebo (1/1,740; 0.06%). In chronic idiopathic constipation clinical trials there was no increase in the frequency of abdominal and pelvic surgeries in active versus placebo groups: 9/1752; 0.5% on Zelnorm (tegaserod maleate) versus 8/861; 0.9% on placebo. A causal relationship between abdominal surgeries and Zelnorm (tegaserod maleate) has not been established.
Other adverse events
The following list of adverse events includes those from phase 3 clinical studies (6 mg b.i.d. or 2 mg b.i.d.) which were reported more frequently (>0.2%) in patients on Zelnorm (tegaserod maleate) than placebo; or which were considered by the investigator to be possibly related to Zelnorm (tegaserod maleate) and reported more frequently (>0.1%) on Zelnorm (tegaserod maleate) than placebo; or which lead to discontinuation more frequently ( 0.1% and in more than 1 patient) on Zelnorm (tegaserod maleate) than placebo. The list also contains those serious adverse events from all clinical trials in patients treated with either 6 mg b.i.d. or 2 mg b.i.d. Zelnorm (tegaserod maleate) which were either considered by the investigator as possibly drug related, or occurred in at least 2 more patients on Zelnorm (tegaserod maleate) than on placebo. Although the events reported occurred during treatment with Zelnorm (tegaserod maleate) , they were not necessarily caused by it.
Eye disorders : Visual disturbance
Immune system disorders : Hypersensitivity reactions
Respiratory, thoracic and mediastinal disorders : Dyspnea, pharyngolaryngeal pain
Surgical and medical procedures : Cholecystectomy
Vascular disorders : Flushing, hypotension
Post Marketing Experience
Voluntary reports of adverse events occurring with the use of Zelnorm (tegaserod maleate) include the following: ischemic colitis (see PRECAUTIONS), mesenteric ischemia, gangrenous bowel, rectal bleeding, syncope, hypotension, hypovolemia, electrolyte disorders, suspected sphincter of Oddi spasm, bile duct stone, cholecystitis with elevated transaminases, and hypersensitivity reaction including rash, urticaria, pruritus and serious allergic Type I reactions. Because these cases are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. No causal relationship between these events and Zelnorm (tegaserod maleate) use has been established.
Post-marketing reports of diarrhea, which can be a pharmacologic response to Zelnorm (tegaserod maleate) , have also been received.
Read the Zelnorm (tegaserod maleate) Side Effects Center for a complete guide to possible side effects
In vitro drug-drug interaction data with tegaserod indicated no inhibition of the cytochrome P450 isoenzymes CYP2C8, CYP2C9, CYP2C19, CYP2E1 and CYP3A4, whereas inhibition of CYP1A2 and CYP2D6 could not be excluded. However, in vivo, no clinically relevant drug-drug interactions have been observed with dextromethorphan (CYP2D6 prototype substrate), and theophylline (CYP1A2 prototype substrate). There was no effect on the pharmacokinetics of digoxin, oral contraceptives, and warfarin. The main human metabolite of tegaserod hydrogen maleate, 5-methoxyindole-3-carboxylic acid glucuronide, did not inhibit the activity of any of the above cytochrome P450 isoenzymes in in vitro tests.
A pharmacokinetic interaction study demonstrated that co-administration of tegaserod and dextromethorphan did not change the pharmacokinetics of either compound to a clinically relevant extent. Dose adjustment of either drug is not necessary when tegaserod is combined with dextromethorphan. Therefore, tegaserod is not expected to alter the pharmacokinetics of drugs metabolized by CYP2D6 (e.g., fluoxetine, omeprazole, captopril).
A pharmacokinetic interaction study demonstrated that co-administration of tegaserod and theophylline did not affect the pharmacokinetics of theophylline. Dose adjustment of theophylline is not necessary when tegaserod is co-administered. Therefore, tegaserod is not expected to alter the pharmacokinetics of drugs metabolized by CYP1A2 (e.g., estradiol, omeprazole).
A pharmacokinetic interaction study with digoxin demonstrated that concomitant administration of tegaserod reduced peak plasma concentration and exposure of digoxin by approximately 15%. This reduction of bioavailability is not considered clinically relevant. When tegaserod is co-administered with digoxin dose adjustment is unlikely to be required.
A pharmacokinetic and pharmacodynamic interaction study with warfarin demonstrated no effect of concomitant administration of tegaserod on warfarin pharmacokinetics and pharmacodynamics. Dose adjustment of warfarin is not necessary when tegaserod is co-administered.
Co-administration of tegaserod did not affect the steady-state pharmacokinetics of ethinylestradiol and reduced peak concentrations and exposure of levonorgestrel by 8%. Tegaserod is not expected to alter the risk of ovulation in subjects taking oral contraceptives. No alteration in oral contraceptive medication is necessary when tegaserod is co-administered.
Last reviewed on RxList: 12/27/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Zelnorm Information
Zelnorm - User Reviews
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.